Publications by authors named "Thomas S Mack"

Claim this Profile
C
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Denise Wolleschak, Thomas S Mack, Florian Perner, Stephanie Frey, Tina M Schnöder

Haematologica· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Sarah Decker, Johannes Finter, Aaron James Forde, Sandra Kissel, Juerg Schwaller, Thomas Sebastian Mack

Mol Cancer Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.
Florian H Heidel, Thomas S Mack, Elena Razumovskaya, Marie-Christine Blum, Daniel B Lipka

Ann Hematol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis